T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).
Nizar M. Tannir,Thomas Powles,Bernard Escudier,Frede Donskov,Viktor Grünwald,Cora N. Sternberg,Manuela Schmidinger,Patrick Schöffski,Cezary Szczylik,Katriina Peltola,Dmitry Nosov,Bohuslav Melichar,Douglas O. Clary,Christian Scheffold,Robert J. Motzer,Toni K. Choueiri +15 more
TL;DR: A retrospective analysis of pts treated with targeted therapy, pts who were older and had mummified appendix found that nephrectomy was more commonly performed in patients with advanced RCC.
Journal ArticleDOI
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Robert J. Motzer,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,Boris Alekseev,Sun Young Rha,Jaime R. Merchan,Jeffrey C. Goh,Anil Kapoor,Ugo De Giorgi,Bohuslav Melichar,Sung-Hoo Hong,Howard Gurney,K. Rodriguez-Lopez,Cixin He,Chinyere E Okpara,J. McKenzie,Toni K. Choueiri +19 more
TL;DR: In the phase 3 CLEAR trial, L+P showed clinically meaningful and statistically significant benefits in PFS (primary endpoint) and OS, and improved ORR compared with S in 1L aRCC (Motzer NEJM 2021) as mentioned in this paper .
Journal ArticleDOI
Immune checkpoint inhibition in urothelial carcinoma
Bernadett Szabados,Thomas Powles +1 more
Journal ArticleDOI
737P Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place
A. Meerveld-Eggink,Niels M. Graafland,Sofie Wilgenhof,J.V. van Thienen,M. Grant,Bernadett Szabados,Yasmin Abu-Ghanem,Ekaterini Boleti,Christian U. Blank,J.B.A.G. Haanen,Thomas Powles,Axel Bex +11 more
Journal ArticleDOI
A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial.
Seth P. Lerner,Thomas Powles,Noah M. Hahn,Thomas A. Gardner,Liang Cheng,James S.A. Green,Daniel M. Berney,D. Taber,J. Landgraf,S. S. Shen,Guru Sonpavde +10 more
TL;DR: While pCR's were observed, the excess toxicity of CGS in the neoadjuvant treatment of miUC precludes further development of the regimen in this population.